Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Starts new research programme in the US on oral mucositis, an inflammation of the mouth that is a common side effect of chemotherapy and radiotherapy. Firm tests its experimental drug candidate XF-73 as potential preventive medicine to ease suffering from oral mucositis. Explains that XF-73 has shown unique antimicrobial properties in phase 2 clinical trials.
The company explains that the global oral mucositis market was worth around $2.2 billion in 2018.
‘A successful preventative product will save healthcare costs and improve patient care whilst supporting a stronger patient to complete their full course of treatment and thereby make a significant contribution to improved clinical outcomes,’ says Chief Executive Officer Neil Clark.
Current stock price: 38.00 pence, down 1.3% on Tuesday
12-month change: down 73%
Copyright 2022 Alliance News Limited. All Rights Reserved.